deferiprone has been researched along with HbS Disease in 23 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 10.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| " The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited." | 9.51 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022) |
| "The present study failed to demonstrate that the use of deferiprone at >90 mg/kg/d was associated with increased risk of agranulocytosis or neutropenia, but did demonstrate more effective liver iron control in iron overload patients." | 7.91 | Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. ( Binding, A; Kuo, KHM; Tomlinson, G; Ward, R, 2019) |
| "Deferiprone use was associated with a significant decline in mean serum ferritin level from 2532±1463 μg/L at baseline to 2176±1144 μg/L (P<0." | 6.75 | The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 6.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| " The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited." | 5.51 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022) |
| "In paediatric patients with transfusion-dependent haemoglobinopathies, deferiprone was effective and safe in inducing control of iron overload during 12 months of treatment." | 5.34 | Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. ( Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A, 2020) |
| "To compare the efficacy and safety of desferrioxamine (DFO), deferiprone (DFP), deferasirox (DFX) and silymarin in patients with either thalassemia or sickle cell disorder through network meta-analysis." | 4.98 | Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. ( Sivaramakrishnan, G; Sridharan, K, 2018) |
| "The present study failed to demonstrate that the use of deferiprone at >90 mg/kg/d was associated with increased risk of agranulocytosis or neutropenia, but did demonstrate more effective liver iron control in iron overload patients." | 3.91 | Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. ( Binding, A; Kuo, KHM; Tomlinson, G; Ward, R, 2019) |
| " In thalassemia major patients, combined therapy with desferrioxamine and deferiprone has maximized tissue iron removal and may reduce the overall occurrence of hemosiderotic heart failure." | 3.73 | Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Moyssakis, I; Polonifi, K; Tsironi, M, 2005) |
| "Deferiprone (Ferriprox®) is an oral iron chelator indicated for the treatment of transfusional iron overload due to thalassemia syndromes and has been recently approved as a treatment for iron overload in adult and pediatric patients with SCD and other anemias." | 3.11 | The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease. ( Fradette, C; Mercier-Ross, J; Rozova, A; Soulières, D; Tricta, F; Tsang, YC, 2022) |
| "Deferiprone use was associated with a significant decline in mean serum ferritin level from 2532±1463 μg/L at baseline to 2176±1144 μg/L (P<0." | 2.75 | The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "Deferiprone was given at a dose of 75 mg/kg daily for 12 months." | 2.71 | Deferiprone as an oral iron chelator in sickle cell disease. ( Douskou, M; Loukopoulos, D; Meletis, J; Ourailidis, A; Papassotiriou, I; Stamoulakatou, A; Terpos, E; Voskaridou, E, 2005) |
| " Dose-response studies showed that incubating thalassemic RBC for 2 hours with L1 concentrations ranging from 0." | 2.68 | Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. ( Abrahamov, A; Goldfarb, A; Grinberg, L; Hebbel, RP; Olivieri, NF; Rachmilewitz, EA; Repka, T; Shalev, O, 1995) |
| "Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
| "For chronic conditions such as thalassemia major, even when oral chelation therapy is available, support by an integrated team including a clinical psychologist and nurse specialist working with the treatment center is recommended to achieve optimal results." | 1.37 | Challenges of adherence and persistence with iron chelation therapy. ( El-Beshlawy, A; Evangeli, M; Porter, JB, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (21.74) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Kwiatkowski, JL | 2 |
| Hamdy, M | 2 |
| El-Beshlawy, A | 5 |
| Ebeid, FSE | 2 |
| Badr, M | 1 |
| Alshehri, A | 1 |
| Kanter, J | 2 |
| Inusa, B | 2 |
| Adly, AAM | 1 |
| Williams, S | 2 |
| Kilinc, Y | 1 |
| Lee, D | 2 |
| Tricta, F | 5 |
| Elalfy, MS | 3 |
| Soulières, D | 1 |
| Mercier-Ross, J | 1 |
| Fradette, C | 2 |
| Rozova, A | 1 |
| Tsang, YC | 2 |
| Veríssimo, MPA | 1 |
| Temin, NT | 1 |
| Maggio, A | 3 |
| Kattamis, A | 1 |
| Felisi, M | 1 |
| Reggiardo, G | 1 |
| Bejaoui, M | 1 |
| Sherief, L | 1 |
| Christou, S | 1 |
| Cosmi, C | 1 |
| Della Pasqua, O | 1 |
| Del Vecchio, GC | 1 |
| Filosa, A | 1 |
| Cuccia, L | 1 |
| Hassab, H | 1 |
| Kreka, M | 1 |
| Origa, R | 1 |
| Putti, MC | 1 |
| Spino, M | 1 |
| Telfer, P | 2 |
| Tempesta, B | 1 |
| Vitrano, A | 2 |
| Zaka, A | 1 |
| Bonifazi, D | 1 |
| Ceci, A | 1 |
| Ballas, SK | 1 |
| Zeidan, AM | 1 |
| Duong, VH | 1 |
| DeVeaux, M | 1 |
| Heeney, MM | 1 |
| Sridharan, K | 1 |
| Sivaramakrishnan, G | 1 |
| Fortin, PM | 1 |
| Fisher, SA | 1 |
| Madgwick, KV | 1 |
| Trivella, M | 1 |
| Hopewell, S | 1 |
| Doree, C | 1 |
| Estcourt, LJ | 1 |
| Hider, RC | 1 |
| Hoffbrand, AV | 2 |
| Binding, A | 1 |
| Ward, R | 1 |
| Tomlinson, G | 1 |
| Kuo, KHM | 1 |
| Calvaruso, G | 1 |
| Di Maggio, R | 1 |
| Ballas, S | 1 |
| Steinberg, MH | 1 |
| Rigano, P | 1 |
| Sacco, M | 1 |
| Renda, D | 1 |
| Barone, R | 1 |
| Inati, A | 1 |
| Khoriaty, E | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| El Alfy, M | 1 |
| Sari, TT | 1 |
| Lee, CL | 1 |
| Porter, JB | 1 |
| Evangeli, M | 1 |
| Ruivard, M | 1 |
| D'Amico, G | 1 |
| Morabito, A | 1 |
| Voskaridou, E | 1 |
| Douskou, M | 1 |
| Terpos, E | 1 |
| Stamoulakatou, A | 1 |
| Meletis, J | 1 |
| Ourailidis, A | 1 |
| Papassotiriou, I | 1 |
| Loukopoulos, D | 1 |
| Tsironi, M | 1 |
| Polonifi, K | 1 |
| Deftereos, S | 1 |
| Farmakis, D | 1 |
| Andriopoulos, P | 1 |
| Moyssakis, I | 1 |
| Aessopos, A | 1 |
| Barton, JC | 1 |
| Shalev, O | 2 |
| Repka, T | 1 |
| Goldfarb, A | 1 |
| Grinberg, L | 1 |
| Abrahamov, A | 1 |
| Olivieri, NF | 3 |
| Rachmilewitz, EA | 1 |
| Hebbel, RP | 2 |
| Collins, AF | 1 |
| Fassos, FF | 1 |
| Stobie, S | 1 |
| Lewis, N | 1 |
| Shaw, D | 1 |
| Fry, M | 1 |
| Templeton, DM | 1 |
| McClelland, RA | 1 |
| Koren, G | 2 |
| Shilalukey, K | 1 |
| Kaufman, M | 1 |
| Bradley, S | 1 |
| Francombe, WH | 1 |
| Amankwah, K | 1 |
| Goldberg, E | 1 |
| Shear, N | 1 |
| AL-Refaie, F | 1 |
| Davis, B | 1 |
| Siritanakatkul, N | 1 |
| Jackson, BF | 1 |
| Cochrane, J | 1 |
| Prescott, E | 1 |
| Wonke, B | 1 |
| Hileti, D | 1 |
| Nortey, P | 1 |
| Hoffbrand, VA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias[NCT02041299] | Phase 4 | 230 participants (Actual) | Interventional | 2014-04-17 | Terminated (stopped due to Difficulties with additional recruitment as pool of potential patients was exhausted, and sufficient information for determination of study outcome measure was already obtained) | ||
| The Pharmacokinetic Profile of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease[NCT01835496] | Phase 1 | 8 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies[NCT01825512] | Phase 3 | 435 participants (Actual) | Interventional | 2014-03-17 | Completed | ||
| A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia[NCT00529152] | Phase 3 | 100 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | milliseconds (Least Squares Mean) |
|---|---|
| Deferiprone | -0.022068 |
| Deferoxamine | -0.021773 |
LIC was measured by MRI. A score >7 mg/g dw is indicative of iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | mg of iron per gram of liver dry weight (Least Squares Mean) |
|---|---|
| Deferiprone | -4.13 |
| Deferoxamine | -4.38 |
Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | micrograms per liter (Least Squares Mean) |
|---|---|
| Deferiprone | -385.83 |
| Deferoxamine | -760.89 |
Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| SF-36 Physical Summary | SF-36 Mental Summary | CHQ-PF50 Physical Summary | CHQ-PF50 Psychosocial Summary | |
| Deferiprone | 43.1 | 44.7 | 29.3 | 42.5 |
| Deferoxamine | 43.0 | 40.9 | 30.5 | 41.3 |
(NCT01835496)
Timeframe: From Day 1 (Dosing) to Day 7 plus/minus 3 days (Follow-up)
| Intervention | participants (Number) |
|---|---|
| Ferriprox | 2 |
(NCT01835496)
Timeframe: From Day 1 (Dosing) to Day 30 post-dose
| Intervention | participants (Number) |
|---|---|
| Ferriprox | 0 |
AUC0-∞ (area under the curve, zero to infinity) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose. (NCT01835496)
Timeframe: 10-hour interval
| Intervention | µg*hr/mL (Mean) | |
|---|---|---|
| AUC0-∞ for serum deferiprone | AUC0-∞ for serum deferiprone 3-O-glucuronide | |
| Ferriprox | 43.37 | 142.7 |
Cmax (maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose. (NCT01835496)
Timeframe: 10-hour interval
| Intervention | μg/mL (Mean) | |
|---|---|---|
| Cmax for serum deferiprone | Cmax for serum deferiprone 3-O-glucuronide | |
| Ferriprox | 17.56 | 32.95 |
T1/2 (apparent terminal elimination half-life) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose. (NCT01835496)
Timeframe: 10-hour interval
| Intervention | hr (Mean) | |
|---|---|---|
| T1/2 for serum deferiprone | T1/2 for serum deferiprone 3-O-glucuronide | |
| Ferriprox | 1.458 | 1.575 |
"Tmax (time to the maximum measured serum concentration) was assessed over a 10-hour interval for deferiprone and its 3-O-glucuronide metabolite. Blood samples were obtained pre-dose and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, and 10 hours post-dose.~The results of the Tmax parameter are reported as the median and range (other parameters are reported as mean and standard deviation)." (NCT01835496)
Timeframe: 10-hour interval
| Intervention | hr (Median) | |
|---|---|---|
| Tmax for serum seferiprone | Tmax for serum deferiprone 3-O-glucuronide | |
| Ferriprox | 1.000 | 2.750 |
Change in cardiac iron concentration (measured using cardiac MRI T2*), assessed as difference between value at 12 months minus value at baseline. MRI T2* is a non-invasive method based on gradient echo (GRE) sequences, where T2* represents the spin-spin relaxation times, measured in milliseconds. The faster the curve decreases (ie, the smaller T2*), the greater amount of iron is in the tissue. Treatment success was assessed as follows: if baseline cardiac T2* was less than 20 ms, an increase of 10% or more after 1 year of treatment was defined as treatment success; if baseline cardiac T2* was more than 20 ms, any increase or a decrease of less than 10% after 1 year of treatment was defined as treatment success. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | milliseconds (ms) (Mean) |
|---|---|
| Deferiprone | 0.488 |
| Deferasirox | 1.121 |
Change in serum ferritin level, assessed as difference between value at 12 months minus value at baseline. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Deferiprone | -397.583 |
| Deferasirox | -398.184 |
Change in liver iron concentration (measured using liver MRI), assessed as difference between value at 12 months minus value at baseline. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | mg/g (Mean) |
|---|---|
| Deferiprone | -0.848 |
| Deferasirox | -2.975 |
Percentage of successfully chelated patients is assessed by serum ferritin levels (in all patients) and cardiac MRI T2* (in patients above 10 years of age able to perform an MRI scan without sedation) (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferiprone | 69 |
| Deferasirox | 80 |
The change in serum ferritin concentration from baseline to week 24 was measured and analyzed for all participants in the study (NCT00529152)
Timeframe: Baseline and 24 weeks
| Intervention | ug/L (Mean) |
|---|---|
| Ferriprox Oral Solution | -355.5 |
Number of Adverse Events over 24 weeks (NCT00529152)
Timeframe: 24 Weeks
| Intervention | Adverse Events (Number) |
|---|---|
| Ferriprox Oral Solution | 212 |
6 reviews available for deferiprone and HbS Disease
| Article | Year |
|---|---|
The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Deferiprone; Deferoxamine; Humans; Iron Ch | 2018 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; H | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Defer | 2018 |
The Role of Deferiprone in Iron Chelation.
Topics: Anemia, Sickle Cell; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Erythr | 2018 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Ir | 2013 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
9 trials available for deferiprone and HbS Disease
| Article | Year |
|---|---|
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron | 2022 |
The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Chelation Therapy; Deferiprone; Female; Humans; Iron | 2022 |
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron C | 2024 |
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Topics: Administration, Oral; Adolescent; Agranulocytosis; Albania; Anemia, Sickle Cell; beta-Thalassemia; C | 2020 |
Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Deferiprone; Deferoxamine; Female; | 2014 |
The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
Topics: Administration, Oral; Agranulocytosis; Anemia, Sickle Cell; beta-Thalassemia; Chemistry, Pharmaceuti | 2010 |
Deferiprone as an oral iron chelator in sickle cell disease.
Topics: Administration, Oral; Adult; Aged; Anemia, Sickle Cell; beta-Thalassemia; Deferiprone; Drug Evaluati | 2005 |
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Deferiprone; Erythrocyte Membrane; Erythrocytes; Humans; Iron | 1995 |
Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelating | 1998 |
8 other studies available for deferiprone and HbS Disease
| Article | Year |
|---|---|
Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Biomarkers; Deferiprone; Humans; Iron; Iro | 2019 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferip | 2010 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasir | 2011 |
Independent clinical trials.
Topics: Anemia, Sickle Cell; Deferiprone; Deferoxamine; Drug Industry; Financial Support; Humans; Multicente | 2004 |
Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Def | 2005 |
Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Child; Deferiprone; Deferoxamine; Dose-Respon | 1994 |
Counseling sexually active teenagers treated with potential human teratogens.
Topics: Adolescent; Adolescent Behavior; Anemia, Sickle Cell; beta-Thalassemia; Contraception Behavior; Coun | 1997 |
Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells.
Topics: Adult; Anemia, Sickle Cell; Biological Transport; Deferiprone; Erythrocytes; Humans; Iron Chelating | 1999 |